Rehan Verjee Purchases 972 Shares of Tyra Biosciences (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Rehan Verjee purchased 972 shares of the business’s stock in a transaction dated Wednesday, September 9th. The shares were purchased at an average price of $20.58 per share, with a total value of $20,003.76. Following the acquisition, the director directly owned 972 shares in the company, valued at approximately $20,003.76. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Tyra Biosciences Price Performance

Shares of TYRA stock traded down $1.53 during trading on Friday, hitting $22.01. 1,548,623 shares of the stock traded hands, compared to its average volume of 916,127. Tyra Biosciences, Inc. has a 52-week low of $11.82 and a 52-week high of $40.65. The firm has a market capitalization of $1.31 billion, a P/E ratio of -9.17 and a beta of 0.73. The firm’s fifty day moving average price is $28.56 and its 200-day moving average price is $31.91.

Tyra Biosciences (NASDAQ:TYRA) last posted its earnings results on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). As a group, equities research analysts expect that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. Wolfe Research initiated coverage on shares of Tyra Biosciences in a report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. HC Wainwright lowered their target price on shares of Tyra Biosciences from $45.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday. Wedbush reiterated an “outperform” rating and set a $53.00 price target on shares of Tyra Biosciences in a research report on Thursday. Jefferies Financial Group reissued a “buy” rating and issued a $42.00 price target on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Tyra Biosciences in a report on Thursday. Eleven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $47.88.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Tidal Investments LLC acquired a new stake in Tyra Biosciences in the 2nd quarter valued at about $943,000. WINTON GROUP Ltd acquired a new position in shares of Tyra Biosciences during the second quarter worth about $537,000. Engineers Gate Manager LP purchased a new stake in shares of Tyra Biosciences during the second quarter worth approximately $1,021,000. Squarepoint Ops LLC increased its stake in shares of Tyra Biosciences by 211.3% during the second quarter. Squarepoint Ops LLC now owns 63,805 shares of the company’s stock worth $2,038,000 after buying an additional 43,311 shares during the period. Finally, California State Teachers Retirement System raised its holdings in Tyra Biosciences by 55,815.5% in the second quarter. California State Teachers Retirement System now owns 783,935 shares of the company’s stock valued at $24,544,000 after acquiring an additional 782,533 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting Tyra Biosciences

Here are the key news stories impacting Tyra Biosciences this week:

• Positive Sentiment: Tyra reported initial results from the Phase II SURF302 trial of oral dabogratinib. Coverage characterized the data as supportive of continued development in FGFR3-driven NMIBC, providing a potential clinical catalyst. Tyra announces initial data from Phase II SURF302 trial of dabogratinib Tyra Biosciences Phase II SURF302 results support LG IR NMIBC with dabogratinib
• Positive Sentiment: Wedbush reaffirmed its “Outperform” rating and maintained a $53 price target, while HC Wainwright kept a “Buy” rating and set a $30 target. These targets imply substantial upside and indicate that analysts still see value in Tyra’s pipeline despite the data reaction.
• Neutral Sentiment: A reported September short-interest figure of zero shares and a zero-day short-interest ratio provides no meaningful evidence of short-covering or increasing bearish positioning; the data also appears inconsistent with the reported trading activity.
• Negative Sentiment: Investors appeared disappointed with the bladder-cancer response data, with multiple reports describing the results as below expectations and the shares declining sharply after the Phase II update. The concern is that dabogratinib’s efficacy may not establish a sufficiently strong competitive position in NMIBC. Tyra shares slip as bladder cancer responses fall short of investor expectations
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Tyra investors. Such investigations can add reputational and legal overhang, although the announcement does not establish wrongdoing. Pomerantz investor alert

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.